Loading
A two-headed antibody that blocks two immune brakes at once extended survival in advanced cervical cancer regardless of PD-L1 status.
COMPASSION-16, also AK104-303, trial NCT04982237 sponsored by Akeso and published in the Lancet in 2024, showed that cadonilimab, a two-headed antibody that blocks PD-1 and CTLA-4 at once, added to first-line platinum and paclitaxel with or without bevacizumab extends survival in persistent, recurrent or metastatic cervical cancer in China regardless of PD-L1 status. It randomised 445 patients and met its primary progression-free and overall survival endpoints with benefit in both PD-L1-positive and PD-L1-negative subgroups, leading to NMPA approval of the first-line combination in 2024. OnCo links it to cervical cancer, bispecific antibodies, PD-1 and CTLA-4 as targets, cadonilimab, bevacizumab and Akeso. It was not approved outside China by 2026, and whether a bispecific offers more than PD-1 blockade alone in PD-L1-negative disease is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
445 enrolled.
Shares Cadonilimab, Akeso, Bispecific antibodies, Cervical cancer.
Shares Recurrent or metastatic cervical cancer, Bevacizumab, Paclitaxel / nab-paclitaxel, Cervical cancer.
Shares Cadonilimab, Akeso, Bispecific antibodies, Paclitaxel / nab-paclitaxel.
Shares Cadonilimab, Akeso, Bispecific antibodies.
Shares Cadonilimab, Akeso, Bispecific antibodies, Paclitaxel / nab-paclitaxel.
Shares Cadonilimab, Akeso, Bispecific antibodies.
Shares Recurrent or metastatic cervical cancer, Bevacizumab, Paclitaxel / nab-paclitaxel, Cervical cancer.
Shares Cadonilimab, Akeso, Bispecific antibodies, Paclitaxel / nab-paclitaxel.